RxDoctor Payments Data

Brennan Tesdahl, MD

Surgery · Omaha, NENPI 1326564055

Payments from drug & device makers

What this record shows

This record is dominated by education: $6,100 of the $10,006 with a category attached, or 61.0%. Intuitive Surgical accounts for 79.0% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $7,988, more than ten times the $156 reported in 2019.

$10,006in general payments, 2019–2025

Across 72 payments — averaging $138.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • Coloplast$496
  • Boston Scientific$415
  • AbbVie$190
  • Baxter Healthcare$150
  • Astellas Pharma US Inc$134
  • plus $713 from 16 others

What the payments were for

  • Travel & lodging$1,39114%
  • Food & beverage$2,51425%
  • Education$6,10061%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,006 in reported general payments places this provider in the 80th percentile of 197 surgery providers in Nebraska.

See all surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$144,411
Medicare patients
434
Services billed
1,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron17$8,666
MyrbetriqMirabegron13$6,655
Tamsulosin Hcl160$2,294
Finasteride51$526
Doxazosin Mesylate26$493
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$278
Cefdinir23$209
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim87$145
Oxybutynin Chloride ErOxybutynin Chloride12$134
Ciprofloxacin Hcl20$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$134$6,65513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 197 surgery providers in Nebraska.

Other surgery in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →